

## New investigator-initiated study on chronic rhinitis shows positive results with K.O.S treatment from Chordate

**The investigator-initiated study The effect of single kinetic oscillation stimulation treatment on nonallergic rhinitis from the University of Helsinki was published in March 2023 and the results show that Chordate's K.O.S treatment provides patients with non-allergic rhinitis with a subjective symptom improvement for at least 1 year, thus possibly decreasing the need for invasive treatment methods.**

"This is another investigator-initiated study that, completely independent of Chordate, shows good results one year after rhinitis treatment with K.O.S. The study results show that K.O.S significantly reduced symptoms for a significant proportion of the 49 patients who participated in the study. This is, of course, another important proof that the treatment can help many people around the world who suffer from chronic rhinitis," says Anders Weilandt, CEO of Chordate.

The study was published in the scientific journal Laryngoscope Investigative Otolaryngology and is the fourth publication in the author Sara Sainio's doctoral thesis [Efficacy and Safety of Novel Medical Devices in Rhinology](#).

[Read more about the completed, ongoing, and planned studies on the K.O.S treatment](#)

**For more information, please contact:**

Anders Weilandt, CEO

[anders.weilandt@chordate.com](mailto:anders.weilandt@chordate.com)

Cell: +46 733-874277

**About Chordate**

Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked a neuromodulation and drug-free treatment technology for chronic migraine and chronic nasal congestion (rhinitis), Kinetic Oscillation Stimulation (K.O.S). The treatment has clinically proven efficacy according to a recent study, and is marketed in Finland, Germany, the UK, Italy, Israel, and Saudi Arabia. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at [www.chordate.com](http://www.chordate.com)

The company's Certified Adviser on Nasdaq First North Growth Market Stockholm is Västra Hamnen Corporate Finance AB.

*N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.*

Press Release  
12 May 2023 10:55:00 CEST

**CHORDATE**  
M E D I C A L

---

**Attachments**

[New investigator-initiated study on chronic rhinitis shows positive results with K.O.S treatment from Chordate](#)